Study on Treatment of Varicose Veins by Endovenous Laser (1940 nm vs 1470 nm)
Launched by CLINIQUE PASTEUR · Dec 15, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different wavelengths of laser treatment for varicose veins in the legs. Specifically, it aims to find out if using a laser with a higher wavelength (1940 nm) is more effective and results in less pain or fewer complications compared to a lower wavelength (1470 nm). Patients who have been diagnosed with varicose veins and are eligible for this treatment may participate in the trial. To join, they need to have specific conditions related to their veins and be able to provide informed consent.
Participants in this study will receive one of the two laser treatments and will be followed for five years to monitor their recovery, any complications, and their overall quality of life. This long-term follow-up will help researchers understand which treatment works better and is safer for patients. It's important to note that certain individuals, such as those with serious health issues or specific vein problems, may not be eligible to participate in the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary insufficiency of the great saphenous vein (GSV) and/or small saphenous vein (SSV)
- • Patient candidate for endothermic treatment of the lower limbs
- • CEAP: C2 - C6
- • Patient with a target vein diameter (GSV and/or SSV) \>= 3 mm throughout the target vein segment
- • Patient affiliated or beneficiary of a social security scheme
- • Patient having signed the informed consent
- Exclusion Criteria:
- • Patient with a current serious pathology and/or a life expectancy of less than 5 years
- • Patient who has had a deep or superficial vein thrombosis in the previous 6 months
- • Obliterating arteriopathy of the lower limb concerned, with an IPS \< 0.8 or \> 1.3
- • Patient with post-thrombotic obstructive syndrome at the popliteal and/or femoral and/or iliac stage on the ipsilateral lower limb
- • Patient with primary or post-thrombotic axial deep venous reflux on the ipsilateral lower limb
- • Suspicion of non-post-thrombotic iliac compression on echo-doppler
- • Contraindication to the planned treatment technique
- • Patient whose geographical distance is not compatible with the follow-up of the study
- • Pregnant or breastfeeding women
- • Patient linguistically or psychologically unable to understand the information given, to give informed consent or to answer the study questionnaires.
- • Protected patients: Adults under guardianship, or other legal protection; Hospitalized without consent.
About Clinique Pasteur
Clinique Pasteur is a renowned clinical trial sponsor dedicated to advancing medical research and improving patient outcomes. With a strong emphasis on innovation and patient care, the institution specializes in conducting high-quality clinical trials across various therapeutic areas. Leveraging state-of-the-art facilities and a team of experienced professionals, Clinique Pasteur fosters collaboration with healthcare providers and research organizations to ensure rigorous study design and adherence to ethical standards. Committed to excellence, the sponsor plays a pivotal role in translating scientific discoveries into effective treatments for the benefit of patients and the broader healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toulouse, , France
Patients applied
Trial Officials
Nicolas NEAUME, MD
Principal Investigator
Clinique Pasteur
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials